The purpose of this study is to evaluate the safety and immunogenicity of V505 in comparison to GARDASIL (TM)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
511
0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 3-dose regimen
Time frame: 4 weeks post dose 3
Geometric mean titers (GMTs) to HPV types contained in the vaccines administered in a 2-dose regimen
Time frame: 4 weeks post dose 2
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.